# US 2026/0242350 A1 · Polycyclic thyroid hormone beta receptor agonist and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242350 A1
- Document ID: US20260242350A1
- Status: Published application
- Kind: A1
- Application number: 19/157,170
- Filed: 2023-12-08
- Published: 2026-08-20
- Earliest claimed: 2023-02-17
- Assignees: Cascade Pharmaceuticals, Inc.
- Applicants: Cascade Pharmaceuticals, Inc.
- Inventors: Jingjing Shi; Shengsheng Yang; Linpei Gong; Peng Wang; Xin Zhu
- Web page: https://patentgrep.com/patent/US20260242350A1

## CPC

- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07B 59/002: {Heterocyclic compounds}
- C07D 215/233: only one oxygen atom which is attached in position 4
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07F 9/60: Quinoline or hydrogenated quinoline ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to a polycyclic thyroid hormone β receptor agonist and use thereof, in particular, to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, a preparation method therefor, and use thereof. The compound or the pharmaceutical composition of the present invention can be used for preparing a drug for preventing, treating, or relieving diseases regulated by the thyroid hormone β receptor.

## Claims

### Claim 1

A compound having a structure of formula (1) or a pharmaceutically acceptable salt thereof:
wherein
G1 is
—O—(C1-6 alkylene)-G2, —NH—(C1-6 alkylene)-G2, —NHCO—(C1-6 alkylene)-G2 or —NHCO-G2;
G2 is —COOH, —P(═O)(OH)2, —P(═O)(OC1-6 alkyl)2,
R4 and R5 are independently H, halogen, —CN, —NH2, —NO2, —OH, C1-6 alkyl, —O(C1-6 alkyl), —COO(C1-6 alkyl), C2-6 alkenyl, C2-6 alkynyl or C3-8 cycloalkyl; said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or C3-8 cycloalkyl is optionally substituted with one or more substituents that are independently deuterium, halogen, —CN, —NH2, —NO2 or —OH;
R2 and R3 are independently H, halogen, —CN, —NH2, —NO2, —OH or C1-6 alkyl; said C1-6 alkyl is optionally substituted with one or more substituents that are independently halogen, —CN, —NH2, —NO2 or —OH;
R6 is H, —COOH, —COO(C1-6 alkyl), —CONH(C1-6 alkyl) or —CONH(C3-8 cycloalkyl); said C1-6 alkyl or C3-8 cycloalkyl is optionally substituted with one or more substituents that are independently halogen, —CN, —NH2, —NO2 or —OH;
R7 and R3 are independently H or deuterium;
each R1 is independently H, halogen, —CN, —NH2, —NO2, —OH, C1-6 alkyl, —O(C1-6 alkyl) or —COO(C1-6 alkyl); said C1-6 alkyl is optionally substituted with one or more substituents that are independently halogen, —CN, —NH2, —NO2 or —OH; and
m is 0, 1, 2, 3 or 4.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
G1 is
—O—(C1-3 alkylene)-G2, —NH—(C1-3 alkylene)-G2, —NHCO—(C1-3 alkylene)-G2 or —NHCO-G2; and
G2 is —COOH, —P(═O)(OH)2, —P(═O)(OC1-3 alkyl)2,

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
R4 and R5 are independently H, halogen, —CN, —NH2, —NO2, —OH, C1-3 alkyl, —O(C1-3 alkyl), —COO(C1-3 alkyl), C2-4 alkenyl, C2-4 alkynyl or C3-6 cycloalkyl; said C1-3 alkyl, C2-4 alkenyl, C2-4 alkynyl or C3-6 cycloalkyl is optionally substituted with one or more substituents that are independently deuterium, halogen, —CN, —NH2, —NO2 or —OH.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
R2 and R3 are independently H, F, Cl, Br, —CN, —NH2 or C1-3 alkyl; said C1-3 alkyl is optionally substituted with one or more substituents that are independently F, Cl, Br, —CN, —NH2, —NO2 or —OH.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
R6 is H, —COOH, —COO(C1-3 alkyl), —CONH(C1-3 alkyl) or —CONH(C3-6 cycloalkyl); said C1-3 alkyl or C3-6 cycloalkyl is optionally substituted with one or more substituents that are independently halogen, —CN, —NH2, —NO2 or —OH.

### Claim 6 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
each R1 is independently H, halogen, —CN, —NH2, —NO2, —OH, C1-3 alkyl, —O(C1-3 alkyl) or —COO(C1-3 alkyl); said C1-3 alkyl is optionally substituted with one or more substituents that are independently halogen, —CN, —NH2, —NO2 or —OH.

### Claim 7

A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

### Claim 8 (depends on 1)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1, and one or more pharmaceutically acceptable carriers.

### Claim 9 (depends on 1)

A method for preventing or treating a disease mediated by a thyroid hormone β receptor in a subject, comprising a step of administering to the subject in need thereof a prophylactically or therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the disease is a metabolic disease.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the disease is nonalcoholic fatty liver disease, dyslipidemia, atherosclerosis, or hypothyroidism.

### Claim 12 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein
R4 and R5 are independently H, —CN, —NH2, —CH3, —CH2CH3, —CH2F, —CHF2, —CDF2, —CF3, —COOCH3, —CH2OH, —CH═CH2, —OCH3, —C≡CH or
R2 and R3 are independently H, F, Cl, Br or —CH3;
R6 is H, —COOH, —COOCH3, —COOCH2CH3, —CONHCH3,
and
each R1 is independently H, F, Cl, Br, —CN, —CH3, —CF3, —OCH3, —OCF3 or —COOCH3.

### Claim 13 (depends on 7)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 7, and one or more pharmaceutically acceptable carriers.

### Claim 14 (depends on 7)

A method for preventing or treating a disease mediated by a thyroid hormone β receptor in a subject, comprising a step of administering to the subject in need thereof a prophylactically or therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 7.

### Claim 15 (depends on 8)

A method for preventing or treating a disease mediated by a thyroid hormone β receptor in a subject, comprising a step of administering to the subject in need thereof a prophylactically or therapeutically effective amount of the pharmaceutical composition according to claim 8.

### Claim 16 (depends on 13)

A method for preventing or treating a disease mediated by a thyroid hormone β receptor in a subject, comprising a step of administering to the subject in need thereof a prophylactically or therapeutically effective amount of the pharmaceutical composition according to claim 13.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the disease is nonalcoholic fatty liver disease, dyslipidemia, atherosclerosis, or hypothyroidism.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the disease is nonalcoholic fatty liver disease, dyslipidemia, atherosclerosis, or hypothyroidism.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the disease is nonalcoholic fatty liver disease, dyslipidemia, atherosclerosis, or hypothyroidism.
